Pim inhibitor therapy (Smi-4a) could also synergize with mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor (U0126) in reducing tumor burden in T-ALL and B-ALL engrafted mouse tumors [166, 167]. The gene discussed is MAPK1; the disease is acute lymphoblastic leukemia.